Compare ORGN & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGN | CLGN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Israel |
| Employees | 91 | N/A |
| Industry | Major Chemicals | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.0M |
| IPO Year | N/A | 2015 |
| Metric | ORGN | CLGN |
|---|---|---|
| Price | $1.25 | $0.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 1.1M | 43.2K |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $503.74 | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.27 |
| 52 Week High | $4.11 | $3.23 |
| Indicator | ORGN | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 36.23 |
| Support Level | $0.15 | $0.35 |
| Resistance Level | $2.33 | $0.45 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 20.41 | 15.64 |
Origin Materials Inc is a technology company with a mission to enable the world's transition to sustainable materials. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include PET circular caps and closures, Para-xylene, carbon black, Levulinic acid, among others, by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.